Calamos Advisors LLC increased its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 492.5% in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 69,222 shares of the biopharmaceutical company’s stock after buying an additional 57,538 shares during the period. Calamos Advisors LLC owned 0.07% of Regeneron Pharmaceuticals worth $30,951,000 at the end of the most recent reporting period.
A number of other institutional investors have also recently added to or reduced their stakes in REGN. Calamos Wealth Management LLC purchased a new position in Regeneron Pharmaceuticals in the 3rd quarter worth approximately $668,000. State of New Jersey Common Pension Fund D bought a new stake in Regeneron Pharmaceuticals during the 3rd quarter valued at $1,341,000. First Trust Advisors LP raised its holdings in Regeneron Pharmaceuticals by 35.2% during the 3rd quarter. First Trust Advisors LP now owns 149,311 shares of the biopharmaceutical company’s stock valued at $66,760,000 after buying an additional 38,887 shares during the last quarter. Xact Kapitalforvaltning AB raised its holdings in Regeneron Pharmaceuticals by 2.9% during the 3rd quarter. Xact Kapitalforvaltning AB now owns 14,375 shares of the biopharmaceutical company’s stock valued at $6,427,000 after buying an additional 402 shares during the last quarter. Finally, Nippon Life Insurance Co. raised its holdings in Regeneron Pharmaceuticals by 29.7% during the 3rd quarter. Nippon Life Insurance Co. now owns 6,522 shares of the biopharmaceutical company’s stock valued at $2,916,000 after buying an additional 1,492 shares during the last quarter. Institutional investors and hedge funds own 67.80% of the company’s stock.
In related news, Director Charles A. Baker sold 2,000 shares of Regeneron Pharmaceuticals stock in a transaction dated Friday, September 29th. The stock was sold at an average price of $450.00, for a total transaction of $900,000.00. Following the sale, the director now directly owns 11,000 shares of the company’s stock, valued at $4,950,000. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Director Michael S. Brown sold 1,500 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Thursday, October 5th. The shares were sold at an average price of $475.00, for a total value of $712,500.00. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 88,942 shares of company stock worth $42,064,076. 10.80% of the stock is owned by insiders.
Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) traded down $10.92 during midday trading on Tuesday, hitting $393.62. The stock had a trading volume of 1,417,500 shares, compared to its average volume of 902,722. The stock has a market capitalization of $41,340.00, a P/E ratio of 35.03, a price-to-earnings-growth ratio of 1.56 and a beta of 1.56. Regeneron Pharmaceuticals, Inc. has a 52 week low of $340.09 and a 52 week high of $543.55. The company has a debt-to-equity ratio of 0.12, a current ratio of 3.63 and a quick ratio of 3.07.
Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings data on Wednesday, November 8th. The biopharmaceutical company reported $3.99 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $3.83 by $0.16. The firm had revenue of $1.50 billion for the quarter, compared to analysts’ expectations of $1.45 billion. Regeneron Pharmaceuticals had a return on equity of 25.73% and a net margin of 23.17%. Regeneron Pharmaceuticals’s revenue for the quarter was up 23.0% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $3.13 earnings per share. sell-side analysts expect that Regeneron Pharmaceuticals, Inc. will post 13.77 earnings per share for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: This piece of content was published by Week Herald and is the sole property of of Week Herald. If you are accessing this piece of content on another site, it was illegally copied and republished in violation of U.S. and international trademark & copyright laws. The original version of this piece of content can be accessed at https://weekherald.com/2017/11/14/calamos-advisors-llc-acquires-57538-shares-of-regeneron-pharmaceuticals-inc-regn.html.
REGN has been the topic of a number of recent analyst reports. Citigroup Inc. reaffirmed a “buy” rating and set a $480.00 price target on shares of Regeneron Pharmaceuticals in a report on Thursday, November 9th. Piper Jaffray Companies reiterated a “buy” rating and set a $540.00 price objective on shares of Regeneron Pharmaceuticals in a research report on Monday. Zacks Investment Research raised shares of Regeneron Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday. BMO Capital Markets set a $491.00 target price on shares of Regeneron Pharmaceuticals and gave the company a “hold” rating in a report on Thursday, August 3rd. Finally, Leerink Swann reaffirmed an “outperform” rating and set a $580.00 price objective (up from $573.00) on shares of Regeneron Pharmaceuticals in a research note on Wednesday, August 9th. Two analysts have rated the stock with a sell rating, fifteen have assigned a hold rating, twelve have given a buy rating and one has given a strong buy rating to the stock. The stock currently has a consensus rating of “Hold” and an average target price of $481.49.
Regeneron Pharmaceuticals Company Profile
Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.
Receive News & Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.